hemay-022
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Oct 14, 2015 (NCT02476539)
Timeline
Indications
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545111 ↗
Also known as
- hemay022
- hemay-022
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06313983 | Phase 3 | Jan 8, 2022 | Hemay Pharmaceutical PTY. LTD. |
| NCT05122494 | Phase 3 | Nov 30, 2021 | Chinese Academy of Medical Sciences, Hemay Pharmaceutical PTY. LTD. |
| NCT04673474 | Phase 1 | Dec 31, 2020 | Hemay Pharmaceutical PTY. LTD. |
| NCT03308201 | Phase 1 | Oct 16, 2017 | Chinese Academy of Medical Sciences, Hemay Pharmaceutical PTY. LTD. |
| NCT02476539 | Phase 1 | Oct 14, 2015 | Hemay Pharmaceutical PTY. LTD. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hemay Pharmaceutical PTY. LTD. | For profit | 5 | 5 | 2 | 2015 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 2 | 2017 |
2 organizations
Page 1 / 1